Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds […]

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Read More

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of […]

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Read More

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.

Lung most cancers is the primary explanation for cancer-related deaths on the earth. Sufferers handled with present chemotherapies for non-small-cell lung cancers (NSCLCs) have a […]

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Read More

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Cells which might be poor in homologous recombination, resembling people who lack useful breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) […]

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Read More